Notch inhibitor: a promising carcinoma radiosensitizer.
Yu SD, Liu FY, Wang QR.
Asian Pac J Cancer Prev. 2012;13(11):5345-51. doi: 10.7314/apjcp.2012.13.11.5345.
HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.
Zhu L, Wu K, Ma S, Zhang S.
Tumori. 2015 May-Jun;101(3):257-62. doi: 10.5301/tj.5000347. Epub 2015 May 1.
Engineering ferroptosis radiosensitizer for SPARC-targeted degradation: A strategy to reverse radioresistant non-small cell lung cancer.
Aishajiang R, Liang Y, Du P, Zhuo X, Liu S, Wei Y, Wang T, Lei P, Yu D, Zhang H.
Biomaterials. 2026 Mar;326:123675. doi: 10.1016/j.biomaterials.2025.123675. Epub 2025 Sep 2.
Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery.
Yin D, Hong X, Wang X, Ding W, Wang C, Qian J, Zhou Y, Sun C, Wu Z.
Curr Oncol. 2025 Dec 1;32(12):680. doi: 10.3390/curroncol32120680.
Dihydroouabain, a novel radiosensitizer for cervical cancer identified by automated high-throughput screening.
Li Z, Tamari K, Seo Y, Minami K, Takahashi Y, Tatekawa S, Otani K, Suzuki O, Isohashi F, Ogawa K.
Radiother Oncol. 2020 Jul;148:21-29. doi: 10.1016/j.radonc.2020.03.047. Epub 2020 Apr 8.
HSA-templated synergistic platform boosts radiotherapy via enhanced radiosensitization and ferroptosis induction.
Fan X, Liu J, Xie S, Tan H, Mi Z, Zhang P, Ma X, Liang Q, Yang M, Ming Y, Rong P.
Drug Resist Updat. 2025 Nov;83:101293. doi: 10.1016/j.drup.2025.101293. Epub 2025 Aug 18.
BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma.
Watanabe J, Clutter MR, Gullette MJ, Sasaki T, Uchida E, Kaur S, Mo Y, Abe K, Ishi Y, Takata N, Natsumeda M, Gadd S, Zhang Z, Becher OJ, Hashizume R.
J Clin Invest. 2024 May 21;134(13):e174794. doi: 10.1172/JCI174794.
Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
Lee YE, Choi SA, Kwack PA, Kim HJ, Kim IH, Wang KC, Phi JH, Lee JY, Chong S, Park SH, Park KD, Hwang DW, Joo KM, Kim SK.
Neuro Oncol. 2017 Aug 1;19(8):1079-1087. doi: 10.1093/neuonc/now300.
Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
Chow Z, Johnson J, Chauhan A, Jeong JC, Castle JT, Izumi T, Weiss H, Townsend CM Jr, Schrader J, Anthony L, Yang ES, Evers BM, Rychahou P.
Cancer Lett. 2024 Aug 1;596:216993. doi: 10.1016/j.canlet.2024.216993. Epub 2024 May 25.
DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
Wang T, Kyle AH, Baker JHE, Liu NA, Banáth JP, Teymori S, Minchinton AI.
DNA Repair (Amst). 2024 Jul;139:103689. doi: 10.1016/j.dnarep.2024.103689. Epub 2024 May 6.
